A Potential Profibrogenic Role of Biliary Epithelium-Derived Cardiotrophin-1 in Pediatric Cholestatic Liver Disease

2015 ◽  
Vol 35 (8) ◽  
pp. 606-612 ◽  
Author(s):  
Xiangwei Hua ◽  
Yuhua Shan ◽  
Dawei Li ◽  
Dongwei Xu ◽  
Jiang Zhang ◽  
...  
Author(s):  
Nehal El Koofy ◽  
Noha Yassin ◽  
Sawsan Okasha ◽  
Hany William ◽  
Wafaa Elakel ◽  
...  

2020 ◽  
Vol 40 (04) ◽  
pp. 403-410
Author(s):  
April O'Brien ◽  
Olga Gasheva ◽  
Gianfranco Alpini ◽  
David Zawieja ◽  
Anatoliy Gashev ◽  
...  

AbstractCholestatic liver disease affects millions of people worldwide and stems from a plethora of causes such as immune dysfunction, genetics, cancerous growths, and lifestyle choices. While not considered a classical lymphatic organ, the liver plays a vital role in the lymph system producing up to half of the body's lymph per day. The lymphatic system is critical to the health of an organism with its networks of vessels that provide drainage for lymphatic fluid and routes for surveilling immune cells. Cholestasis results in an increase of inflammatory cytokines, growth factors, and inflammatory infiltrate. Left unchecked, further disease progression will include collagen deposition which impedes both the hepatic and lymphatic ducts, eventually resulting in an increase in hepatic decompensation, increasing portal pressures, and accumulation of fluid within the abdominal cavity (ascites). Despite the documented interplay between these vital systems, little is known about the effect of liver disease on the lymph system and its biological response. This review looks at the current cholestatic literature from the perspective of the lymphatic system and summarizes what is known about the role of the lymph system in liver pathogenesis during hepatic injury and remodeling, immune-modulating events, or variations in interstitial pressures.


2018 ◽  
Vol 2 (2) ◽  
pp. 51-56
Author(s):  
Zoya Chaudhry ◽  
Sylviane Forget ◽  
Van-Hung Nguyen ◽  
Najma Ahmed

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
James H. Tabibian ◽  
Jayant A. Talwalkar ◽  
Keith D. Lindor

Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.


2013 ◽  
Vol 18 (3) ◽  
pp. 241-346 ◽  
Author(s):  
Sarah Dillon ◽  
Joseph D. Tobias

Intractable itching is a symptom of cholestatic liver disease of various causes that is bothersome and difficult to manage. Although treatment of the primary cause of cholestasis is paramount in resolving the issue, given the debilitating consequences of pruritus, symptomatic treatment is frequently necessary. Although many medications including cholestyramine, rifampin, opioid antagonists (i.e., naloxone, naltrexone), phenobarbital, and antihistamines have been used to treat cholestatic-induced pruritus, none has resulted in uniform success. We report anecdotal success with the use of ondansetron to treat pruritus associated with cholestasis following prolonged intensive care unit course of a 16-year-old. The theories accounting for pruritus with cholestasis are presented, treatment options are reviewed, and the role of ondansetron in the treatment of pruritus is discussed.


1997 ◽  
Vol 25 (3) ◽  
pp. 301-306 ◽  
Author(s):  
James E. Heubi ◽  
James V. Higgins ◽  
Eric A. Argao ◽  
Rosa I. Sierra ◽  
Bonny L. Specker

2018 ◽  
Vol 42 (4) ◽  
pp. 296-305 ◽  
Author(s):  
Laurent Ehrlich ◽  
Marinda Scrushy ◽  
Fanyin Meng ◽  
Terry C. Lairmore ◽  
Gianfranco Alpini ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e78856 ◽  
Author(s):  
Joerg Latus ◽  
Reinhild Klein ◽  
Ina Koetter ◽  
Matthias Schwab ◽  
Peter Fritz ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1876 ◽  
Author(s):  
Lorenzo Norsa ◽  
Laura Zazzeron ◽  
Marialaura Cuomo ◽  
Laura Claut ◽  
Anna Marta Clotilde Bulfamante ◽  
...  

Vitamin A is a fundamental micronutrient that regulates various cellular patterns. Vitamin A deficiency (VAT) is a worldwide problem and the primary cause of nocturnal blindness especially in low income countries. Cystic fibrosis (CF) is a known risk factor of VAD because of liposoluble vitamin malabsorption due to pancreatic insufficiency. We describe a case of a 9-year-old girl who experienced recurrent episodes of nocturnal blindness due to profound VAD. This little girl is paradigmatic for the explanation of the key role of the gut–liver axis in vitamin A metabolism. She presents with meconium ileus at birth, requiring intestinal resection that led to a transient intestinal failure with parenteral nutrition need. In addition, she suffered from cholestatic liver disease due to CF and intestinal failure-associated liver disease. The interaction of pancreatic function, intestinal absorption and liver storage is fundamental for the correct metabolism of vitamin A.


Sign in / Sign up

Export Citation Format

Share Document